Navigation Links
NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting
Date:2/18/2011

ROCKVILLE, Md., Feb. 18, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage biopharmaceutical company, today presented the final safety and immunogenicity results from its 2009 H1N1 virus-like particle (VLP) pandemic influenza vaccine clinical trial in Mexico at the invitation-only 7th World Health Organization Meeting (WHO) on Evaluation of Pandemic Influenza Vaccines in Clinical Trials. The meeting was held at the WHO headquarters in Geneva, Switzerland where Dr. Gregory Glenn, Chief Medical Officer of Novavax, presented the findings at a session entitled: "Pandemic and Potentially Pandemic Vaccines Developed Using New Technologies."  Dr. Glenn's presentation was entitled: "Phase II randomized, double-blind, placebo-controlled trial of a novel (H1N1) influenza VLP vaccine" and is available at www.novavax.com under the Investors/Events tab.

In this randomized, double-blind, placebo-controlled Phase II trial, Novavax's H1N1 VLP vaccine was administered in a single-dose regimen to over 3,000 subjects. The study found that the vaccine exceeded the immunogenicity criteria for seasonal influenza vaccine licensure at all dose levels including the 5mcg dose. Additionally, a single administration of the VLP vaccine induced high levels of hemaglutinin inhibition (HAI) titers in subjects without pre-existing detectable immunity to this pandemic influenza strain. Together, the data indicate that the H1N1 VLP vaccine was well-tolerated and immunogenic.

Dr. Glenn commented:  "This trial was an important milestone for our influenza vaccine program and demonstrated the potential of our recombinant vaccine technology.  The data indicate that our VLP vaccine was well-tolerated and generated robust immunogenicity at all dose levels, including the 5mcg dose. The single-dose seroprotection data in patients who had no pre-existing immunity (seronegatives) achieved protective titers in up
'/>"/>

SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. NOVAVAX to Present H1N1 VLP Influenza Vaccine Clinical Data at 7th World Health Organization (WHO) Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials
2. NOVAVAX Receives FDA Clearance to Launch Phase I RSV Vaccine Clinical Trial
3. NOVAVAX to Present at Lazard 7th Annual Healthcare Conference
4. NOVAVAX Reports Third Quarter 2010 Financial Results
5. Novavax to Report Third Quarter 2010 Financial Results on November 5, 2010
6. NOVAVAX to Present at BIO Investor Forum
7. NOVAVAX to Present at Stifel Nicolaus Conference
8. NOVAVAX Endorses New U.S. Initiatives to Develop Medical Countermeasures
9. NOVAVAX Announces Issuance of Key U.S. Patent for Influenza Virus-Like Particle (VLP) Vaccines
10. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2010
11. Novavaxs Seasonal Influenza VLP Vaccine Candidate Shows Positive Results in a Phase II Clinical Trial in Older Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... CHINA , May 24, 2013 ... or the "Company"), a leading China ... manufacturing and marketing biopharmaceutical products, announced today that, ... "EGM"), the Company,s shareholders voted in favor of ... announced agreement and plan of merger dated February ...
(Date:5/23/2013)... -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ) today ... Science Firm of the Year by the Tech Council of ... the TCM,s 25 th Annual Tech Awards Celebration held ... Celebration recognizes the leaders and innovators in the technology and ... the surrounding regions. "We are deeply honored ...
(Date:5/23/2013)... de mayo de 2013  Volcano Corporation (NASDAQ: ... fabricante de herramientas de precisión para terapia guiadas ... la enfermedad vascular periférica y coronaria, anunció hoy ... enosine V asodilator I ndependent ... sesión de ensayo clínico hot line late breaking ...
Breaking Medicine Technology:3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
(Date:5/23/2013)... 2013 Susquehanna Health is ... comprehensive babysitting training course for adolescents age 11 and ... Indianapolis pediatrician Dr. Patricia Keener after a colleague’s toddler ... adult sitter who didn’t know how to provide first ... with a medical basis that aims to reduce the ...
(Date:5/23/2013)... to its destruction inside a cell, a cancer-promoting ... thwart the development of tumor-suppressing microRNAs (miRNAs) before ... publication at Nature . , Under conditions ... epidermal growth factor receptor (EGFR) gums up the ... scientists at The University of Texas MD Anderson ...
(Date:5/23/2013)... used next generation genomic analysis to determine that some ... genetic origins, which may help in predicting cancer progression. ... Cancer Research . , "This is the first study ... adjacent Gleason patterns in the same tumor allowing us ... Cheville, M.D., Mayo Clinic pathologist and one of the ...
(Date:5/23/2013)... The Rottenstein Law Group LLP, a New ... Tylenol Lawsuit Information Center at http://www.rotlaw.com/tylenol , dedicated ... who are considering filing lawsuits. , The painkiller ... liver damage, according to a 2009 report from the ... communication,” the FDA warned consumers against using more than ...
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 Dr. ... her new charitable organization in Orange County, OCCares , ... in Orange County. The event details are as follows: ... Orangewood Academy Auditorium, 13732 Clinton Street, Garden Grove, CA 92843 ... pop crossover music by Christian vocalists Charmaine & Jonathan Thulin. ...
Breaking Medicine News(10 mins):Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3Health News:Mayo Clinic genomic analysis lends insight to prostate cancer 2Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 3
... 67-Year-Old Great-Grandmother & Geriatric Care Manager Marion Somers, PhD, Will Visit 15 ... ... Politicians, NEW YORK, Sept. 24 Leading ... today kicked off her second national bus tour this year to raise,awareness ...
... Campaign Supports Susan G. Komen for the Cure with its ... Auction this October, WHAT: Emmy Award-winning journalist and TV personality Cristina ... Project Pink Campaign. Munchkin, Inc. ... products -- is once again reminding women everywhere "Don,t Duck a ...
... YORK, Sept. 24 There is clear evidence,that ... added to U.S. water,supplies, present potential risks to ... (NRC) first-ever published review of the,fluoride/thyroid literature.(A) ... 2/3 of U.S.,public water supplies, ostensibly to reduce ...
... 2007 -- A new study reports important evidence ... diagnosed with schizophrenia. Schizophrenia is considered one ... disorders, which has three distinct facets, often referred ... reduced capacity for pleasure), and cognitive (impairments in ...
... methods significantly raise exam rate, study finds , MONDAY, ... doctors, offices can improve colorectal cancer screening rates, a ... most common kind of cancer and the third leading ... patients don,t experience any symptoms until the disease is ...
... Health Solutions, Inc.,("SXC" or the "Company") (NASDAQ: SXCI ... services, announces that Gordon S. Glenn,Chairman and Chief Executive ... Officer, will present at the 2007 UBS Global Life,Sciences ... SXC,s presentation,will take place on Tuesday, September 25, 2007 ...
Cached Medicine News:Health News:Elder Care Author Doctor Marion Launches Second National Tour to Raise Awareness About Aging & Elder Care Issues in America 2Health News:Cristina Saralegui Joins Celebrities Including Matthew McConaughey, Courteney Cox and Mariska Hargitay to Raise Money for Breast Cancer Research 2Health News:Fluoride Damages the Thyroid, Report Shows 2Health News:Potential new approach to treat cognitive impairments in schizophrenia 2Health News:Doctors' Office Outreach Boosts Colon Cancer Screening 2